Allergan acquired Anterios, a clinical-stage biopharmaceutical company developing topical botulinum toxin products and proprietary needle-free delivery (NDS) platform. Upfront payment of $90M plus undisclosed development and commercialization milestones. Pre-closing, Anterios spun out certain assets to Eirion Therapeutics.